Chris P. Recknor
Center for Advanced Research and Education
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Chris P. Recknor as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:27 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04663737 · Evaluating Safety, Pharmacokinetics and Clinical Benefit of Silmitasertib (CX-4945) in Subjects With Moderate COVID-19Senhwa Biosciences, Inc. · completed · Covid19 · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:27 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:27 UTC. The ranking covers the 200 most relevant of 12 PubMed records, and a shared surname and initials can bring in a namesake. All 12 on PubMed
- Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures.J Bone Miner Res · 2010400 citationsRCR 14.8
- Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial.Lancet Diabetes Endocrinol · 2015319 citationsRCR 12.7
- Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial.J Am Dent Assoc · 2008105 citationsRCR 3.5
- The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures.Osteoporos Int · 2012105 citationsRCR 3.9
- Skeletal histomorphometry in subjects on teriparatide or zoledronic acid therapy (SHOTZ) study: a randomized controlled trial.J Clin Endocrinol Metab · 201263 citationsRCR 2.3
- Remodeling- and Modeling-Based Bone Formation With Teriparatide Versus Denosumab: A Longitudinal Analysis From Baseline to 3 Months in the AVA Study.J Bone Miner Res · 201862 citationsRCR 2.9
- The Effect of Discontinuing Treatment With Blosozumab: Follow-up Results of a Phase 2 Randomized Clinical Trial in Postmenopausal Women With Low Bone Mineral Density.J Bone Miner Res · 201555 citationsRCR 2.0
- 54 citationsRCR 1.4
- Differential Effects of Teriparatide and Denosumab on Intact PTH and Bone Formation Indices: AVA Osteoporosis Study.J Clin Endocrinol Metab · 201652 citationsRCR 2.4
- A Longitudinal Study of Skeletal Histomorphometry at 6 and 24 Months Across Four Bone Envelopes in Postmenopausal Women With Osteoporosis Receiving Teriparatide or Zoledronic Acid in the SHOTZ Trial.J Bone Miner Res · 201637 citationsRCR 1.6